Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0053
¿Comprende? Assessing the Readability of Freely Available Spanish-Language Online Patient Education Materials for Rheumatologic Diseases
Healthcare Disparities in Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 0090
110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing- 9:00AM-11:00AM
-
Abstract Number: 0412
2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0073
A Cross-Species Map of Neutrophil Inflammatory Responses
Innate Immunity Poster- 9:00AM-11:00AM
-
Abstract Number: 0305
A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0399
A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma
Systemic Sclerosis & Related Disorders – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 0106
A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0026
A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
Fibromyalgia & Other Clinical Pain Syndromes Poster- 9:00AM-11:00AM
-
Abstract Number: 0201
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0199
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0385
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis
Systemic Sclerosis & Related Disorders – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 0241
A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis